Compare ELOG & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELOG | BCTX |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 17.0M |
| IPO Year | 2025 | N/A |
| Metric | ELOG | BCTX |
|---|---|---|
| Price | $1.40 | $4.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | ★ 2.0M | 858.8K |
| Earning Date | 02-10-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.27 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $45,962,309.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | $9.10 | ★ N/A |
| Revenue Growth | ★ 10.64 | N/A |
| 52 Week Low | $0.88 | $4.10 |
| 52 Week High | $3.60 | $98.20 |
| Indicator | ELOG | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 37.42 |
| Support Level | N/A | $4.10 |
| Resistance Level | N/A | $4.56 |
| Average True Range (ATR) | 0.00 | 0.71 |
| MACD | 0.00 | -0.25 |
| Stochastic Oscillator | 0.00 | 3.12 |
Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products. Its segments are Transportation services and Warehouse subleasing services. The group generates the majority of its revenue from Transportation services.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.